• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Sera Prognostics Inc.

    6/1/26 4:46:27 PM ET
    $SERA
    Medical Specialities
    Health Care
    Get the next $SERA alert in real time by email
    DEFA14A 1 sera-defa14a-2026-additi.htm DEFA14A DEFA14A

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

    SCHEDULE 14A

    Proxy Statement Pursuant to Section 14(a) of

    the Securities Exchange Act of 1934

    (Amendment No. )

     

    Filed by the Registrant ☒

    Filed by a Party other than the Registrant ☐

    Check the appropriate box:

    ☐

    Preliminary Proxy Statement

     

     

    ☐

    Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

     

     

    ☐

    Definitive Proxy Statement

     

     

    ☒

    Definitive Additional Materials

     

     

    ☐

    Soliciting Material Pursuant to §240.14a-12

    SERA PROGNOSTICS, INC.

     

    (Name of Registrant as Specified In Its Charter)

     

    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)

    Payment of Filing Fee (Check the appropriate box):

    ☒

     

    No fee required.

    ☐

     

    Fee paid previously with preliminary materials.

    ☐

     

    Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11

     


     

    SUPPLEMENT TO THE PROXY STATEMENT

    FOR THE ANNUAL MEETING OF STOCKHOLDERS

    OF SERA PROGNOSTICS, INC.

    TO BE HELD ON JUNE 4, 2026

    June 1, 2026

    On or about April 24, 2026, Sera Prognostics, Inc. (the “Company”) commenced mailing to its stockholders a notice containing instructions on how to access a definitive proxy statement, dated April 24, 2026 (the “Proxy Statement”), for the Company’s annual meeting of stockholders to be held on June 4, 2026 (the “Annual Meeting”). This proxy statement supplement (the “Supplement”), which describes a recent change in the proposed nominees for election to the Company’s board of directors (the “Board”), should be read in conjunction with the Proxy Statement. To the extent the information in this Supplement differs from or updates information in the Proxy Statement, our stockholders should rely on the information contained in this Supplement.

    Withdrawal of Nominee for Election as Director

    On May 26, 2026, Jeffrey T. Elliott, a member of the Board and nominee for re-election as a director at the Annual Meeting, submitted his resignation from the Board, effective the date of the Annual Meeting (June 4, 2026). Mr. Elliott’s resignation was not as a result of any disagreement between Mr. Elliott and the Company on any matter relating to the Company’s operations, policies or practices. Mr. Elliott’s term as a director was scheduled to expire at the Annual Meeting and he was listed as a nominee for re-election in the Proxy Statement. In connection with his resignation, the nomination of Mr. Elliott for re-election is withdrawn, and he is no longer a nominee. The Board does not plan to substitute another nominee for election as a director at the Annual Meeting in place of Mr. Elliott. The Board has also reduced the size of the Board to seven directors.

    None of the other agenda items presented in the Proxy Statement are affected by this Supplement.

    Voting Matters

    All nominees, other than Mr. Elliott, named in the Proxy Statement continue to stand for re-election at the Annual Meeting. Notwithstanding the withdrawal of Mr. Elliott’s nomination, the proxy card included with the Proxy Statement remains valid, and no new proxy cards will be distributed. All proxy cards, votes and voting instructions submitted by stockholders will be voted at the Annual Meeting unless revoked, except that any votes cast for Mr. Elliott will be disregarded. If you have not yet returned your proxy card, voted or submitted your voting instructions, please do so promptly so that your vote will be counted at the Annual Meeting.

    If you have already returned your proxy card, voted or provided voting instructions, you do not need to take any action unless you wish to change your vote.

    Information about how to vote your shares, or revoke your proxy, vote or voting instructions, is available in the Proxy Statement.

     


    Get the next $SERA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SERA

    DatePrice TargetRatingAnalyst
    6/4/2026$6.00Buy
    Craig Hallum
    12/15/2025$5.00Buy
    Jefferies
    3/30/2022$18.00 → $4.00Buy → Neutral
    Citigroup
    11/19/2021$19.00Outperform
    Oppenheimer
    10/15/2021Outperform
    Cowen
    8/9/2021Outperform
    William Blair
    8/9/2021Outperform
    Cowen
    8/9/2021$18.00Buy
    Citigroup
    More analyst ratings

    $SERA
    SEC Filings

    View All

    SEC Form DEFA14A filed by Sera Prognostics Inc.

    DEFA14A - SERA PROGNOSTICS, INC. (0001534969) (Filer)

    6/1/26 4:46:27 PM ET
    $SERA
    Medical Specialities
    Health Care

    Sera Prognostics Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - SERA PROGNOSTICS, INC. (0001534969) (Filer)

    6/1/26 4:44:21 PM ET
    $SERA
    Medical Specialities
    Health Care

    SEC Form 10-Q filed by Sera Prognostics Inc.

    10-Q - SERA PROGNOSTICS, INC. (0001534969) (Filer)

    5/6/26 4:08:39 PM ET
    $SERA
    Medical Specialities
    Health Care

    $SERA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    SERA PROGNOSTICS ANNOUNCES BOARD TRANSITION

    SALT LAKE CITY, June 1, 2026 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ:SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that Jeff Elliott has notified the Company of his intention to step down from its Board of Directors, effective June 4, 2026, and that he will not stand for re-election at the Company's upcoming Annual Meeting of Shareholders. Mr. Elliott has served on Sera's Board since March 2025, providing strategic guidance and leadership during a period of growth and development for the Comp

    6/1/26 4:05:00 PM ET
    $SERA
    Medical Specialities
    Health Care

    SERA PROGNOSTICS ANNOUNCES CONFERENCE CALL AND WEBCAST OF FIRST QUARTER FISCAL YEAR 2026 FINANCIAL RESULTS ON MAY 6, 2026

    SALT LAKE CITY, April 22, 2026 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ:SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced it will report first quarter fiscal year 2026 financial results on Wednesday May 6, 2026, after the close of the market. The Company will host a corresponding conference call and live webcast to discuss operational highlights, financial results and key topics at 5:00 p.m. Eastern Time. A press release outlining the financial results and highlights will be publicly distributed before the call.

    4/22/26 8:05:00 AM ET
    $SERA
    Medical Specialities
    Health Care

    SERA PROGNOSTICS REPORTS FOURTH QUARTER AND FULL YEAR 2025 FINANCIAL RESULTS

    SALT LAKE CITY, March 18, 2026 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ:SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced financial results for the fourth quarter and full year ended December 31, 2025. Key 2025 and Recent Highlights:Data Generation Published Landmark PRIME Study Demonstrating PreTRM® Blood Test Reduces Earliest Preterm Births and Newborn Complications: In January 2026, the PRIME Study, a randomized controlled trial of 5,018 women,

    3/18/26 4:05:00 PM ET
    $SERA
    Medical Specialities
    Health Care

    $SERA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    General Counsel Jackson Benjamin was granted 5,000 shares, increasing direct ownership by 3% to 163,935 units (SEC Form 4)

    4 - SERA PROGNOSTICS, INC. (0001534969) (Issuer)

    6/1/26 4:49:50 PM ET
    $SERA
    Medical Specialities
    Health Care

    Chief Commercial Officer Anderson Dyaarl Lee Jr. was granted 3,168 shares, increasing direct ownership by 4% to 82,737 units (SEC Form 4)

    4 - SERA PROGNOSTICS, INC. (0001534969) (Issuer)

    6/1/26 4:49:25 PM ET
    $SERA
    Medical Specialities
    Health Care

    SEC Form 4 filed by Chief Data Officer Kearney Paul

    4 - SERA PROGNOSTICS, INC. (0001534969) (Issuer)

    5/6/26 4:12:10 PM ET
    $SERA
    Medical Specialities
    Health Care

    $SERA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Craig Hallum initiated coverage on Sera Prognostics with a new price target

    Craig Hallum initiated coverage of Sera Prognostics with a rating of Buy and set a new price target of $6.00

    6/4/26 7:57:28 AM ET
    $SERA
    Medical Specialities
    Health Care

    Jefferies initiated coverage on Sera Prognostics with a new price target

    Jefferies initiated coverage of Sera Prognostics with a rating of Buy and set a new price target of $5.00

    12/15/25 10:01:13 AM ET
    $SERA
    Medical Specialities
    Health Care

    Sera Prognostics downgraded by Citigroup with a new price target

    Citigroup downgraded Sera Prognostics from Buy to Neutral and set a new price target of $4.00 from $18.00 previously

    3/30/22 7:52:32 AM ET
    $SERA
    Medical Specialities
    Health Care

    $SERA
    Leadership Updates

    Live Leadership Updates

    View All

    SERA PROGNOSTICS ANNOUNCES BOARD TRANSITION

    SALT LAKE CITY, June 1, 2026 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ:SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that Jeff Elliott has notified the Company of his intention to step down from its Board of Directors, effective June 4, 2026, and that he will not stand for re-election at the Company's upcoming Annual Meeting of Shareholders. Mr. Elliott has served on Sera's Board since March 2025, providing strategic guidance and leadership during a period of growth and development for the Comp

    6/1/26 4:05:00 PM ET
    $SERA
    Medical Specialities
    Health Care

    Quanterix Announces Board and Leadership Changes to Support Next Stage of Growth

    Appoints Garret Hampton and Alan Sachs to the Board Appoints William Donnelly as Executive Chair of the Board and Jeffrey Elliott as Lead Independent Director Quanterix Corporation ("Quanterix" or the "Company") (NASDAQ:QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced a series of leadership and governance enhancements designed to support the Company's next phase of growth. These changes include the appointment of two highly accomplished life sciences executives, Garret Hampton, Ph.D., and Alan Sachs, M.D., Ph.D., to the Company's Board of Directors, effective immediately. Dr. Hampton most recently served as

    11/20/25 4:15:00 PM ET
    $EXAS
    $IDYA
    $ILMN
    Medical Specialities
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Industrial Machinery/Components

    Sera Prognostics Names Dr. Tiffany Inglis Chief Medical Officer

    SALT LAKE CITY, Oct. 1, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ:SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker testing to help deliver information to doctors and patients, today announced the appointment of Tiffany Inglis, MD, FACOG, as Chief Medical Officer. With extensive clinical leadership expertise, Dr. Inglis will lead Sera's clinical operations to establish the company as a leader in women's health diagnostics to improve the health of pregnant women and newborns. Dr. Inglis joins Se

    10/1/25 8:05:00 AM ET
    $SERA
    Medical Specialities
    Health Care

    $SERA
    Financials

    Live finance-specific insights

    View All

    SERA PROGNOSTICS ANNOUNCES CONFERENCE CALL AND WEBCAST OF FIRST QUARTER FISCAL YEAR 2026 FINANCIAL RESULTS ON MAY 6, 2026

    SALT LAKE CITY, April 22, 2026 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ:SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced it will report first quarter fiscal year 2026 financial results on Wednesday May 6, 2026, after the close of the market. The Company will host a corresponding conference call and live webcast to discuss operational highlights, financial results and key topics at 5:00 p.m. Eastern Time. A press release outlining the financial results and highlights will be publicly distributed before the call.

    4/22/26 8:05:00 AM ET
    $SERA
    Medical Specialities
    Health Care

    SERA PROGNOSTICS ANNOUNCES CONFERENCE CALL AND WEBCAST OF FOURTH QUARTER AND FISCAL YEAR 2025 FINANCIAL RESULTS ON MARCH 18, 2026

    SALT LAKE CITY, March 4, 2026 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ:SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced it will report fourth quarter and fiscal year 2025 financial results on Wednesday March 18, 2026, after the close of the market. The Company will host a corresponding conference call and live webcast to discuss operational highlights, financial results and key topics at 5:00 p.m. Eastern Time. A press release outlining the financial results and highlights will be publicly distributed before the call.

    3/4/26 8:05:00 AM ET
    $SERA
    Medical Specialities
    Health Care

    SERA PROGNOSTICS REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS

    SALT LAKE CITY, Nov. 13, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ:SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced financial results for the third quarter of 2025 ended September 30, 2025. Third Quarter and Recent Highlights: Meaningful progress on payer initiatives, including an inaugural pilot in Nevada actively enrolling Medicaid patients, while engaging with multiple payers across thirteen states, collectively representing a significant

    11/13/25 4:05:00 PM ET
    $SERA
    Medical Specialities
    Health Care

    $SERA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Sera Prognostics Inc.

    SC 13G/A - SERA PROGNOSTICS, INC. (0001534969) (Subject)

    11/14/24 5:46:12 PM ET
    $SERA
    Medical Specialities
    Health Care

    Amendment: SEC Form SC 13G/A filed by Sera Prognostics Inc.

    SC 13G/A - SERA PROGNOSTICS, INC. (0001534969) (Subject)

    11/4/24 7:19:49 AM ET
    $SERA
    Medical Specialities
    Health Care

    SEC Form SC 13G filed by Sera Prognostics Inc.

    SC 13G - SERA PROGNOSTICS, INC. (0001534969) (Subject)

    4/1/24 7:33:43 PM ET
    $SERA
    Medical Specialities
    Health Care